Some searches may not work properly. We apologize for the inconvenience.
My bibliography Save this articleUsing health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
Author
Abstract
Suggested Citation
DOI: 10.1007/s10198-017-0871-0
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- J.- Graf v. d. Schulenburg & Christoph Vauth & Thomas Mittendorf & Wolfgang Greiner, 2007. "Methods for determining cost-benefit ratios for pharmaceuticals in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(1), pages 5-31, September.
- Chalkidou, Kalipso, 2012. "Evidence and values: paying for end-of-life drugs in the British NHS," Health Economics, Policy and Law, Cambridge University Press, vol. 7(4), pages 393-409, October.
- Calltorp, Johan, 1999. "Priority setting in health policy in Sweden and a comparison with Norway," Health Policy, Elsevier, vol. 50(1-2), pages 1-22, December.
- Shah, Koonal K. & Cookson, Richard & Culyer, Anthony J. & Littlejohns, Peter, 2013.
"NICE's social value judgements about equity in health and health care,"
Health Economics, Policy and Law, Cambridge University Press, vol. 8(2), pages 145-165, April.
- Koonal K Shah & Richard Cookson & Anthony J Culyer & Peter Littlejohns, 2011. "NICE's Social Value Judgements about Equity in Health and Health Care," Working Papers 070cherp, Centre for Health Economics, University of York.
- Dana Goldman & Darius Lakdawalla & Tomas J. Philipson & Wesley Yin, 2010. "Valuing health technologies at nice: recommendations for improved incorporation of treatment value in HTA," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1109-1116, October.
- Mikael Svensson & Fredrik Nilsson & Karl Arnberg, 2015. "Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness," PharmacoEconomics, Springer, vol. 33(11), pages 1229-1236, November.
- Margreet Franken & Fredrik Nilsson & Frank Sandmann & Anthonius Boer & Marc Koopmanschap, 2013. "Unravelling Drug Reimbursement Outcomes: A Comparative Study of the Role of Pharmacoeconomic Evidence in Dutch and Swedish Reimbursement Decision Making," PharmacoEconomics, Springer, vol. 31(9), pages 781-797, September.
- Kevin Marsh & Tereza Lanitis & David Neasham & Panagiotis Orfanos & Jaime Caro, 2014. "Assessing the Value of Healthcare Interventions Using Multi-Criteria Decision Analysis: A Review of the Literature," PharmacoEconomics, Springer, vol. 32(4), pages 345-365, April.
- Golan, Ofra & Hansen, Paul & Kaplan, Giora & Tal, Orna, 2011. "Health technology prioritization: Which criteria for prioritizing new technologies and what are their relative weights?," Health Policy, Elsevier, vol. 102(2), pages 126-135.
- Banta, David, 2003. "The development of health technology assessment," Health Policy, Elsevier, vol. 63(2), pages 121-132, February.
- Dana Goldman & Darius Lakdawalla & Tomas J. Philipson & Wesley Yin, 2010. "Erratum: Valuing health technologies at NICE: recommendations for improved incorporation of treatment value in HTA," Health Economics, John Wiley & Sons, Ltd., vol. 19(12), pages 1510-1510, December.
- Jon Sussex & Adrian Towse & Nancy Devlin, 2013. "Operationalizing Value-Based Pricing of Medicines," PharmacoEconomics, Springer, vol. 31(1), pages 1-10, January.
- Claus Runge, 2012. "Separating the wheat from the chaff," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(2), pages 121-126, April.
- Jena, Anupam B. & Philipson, Tomas J., 2013.
"Endogenous cost-effectiveness analysis and health care technology adoption,"
Journal of Health Economics, Elsevier, vol. 32(1), pages 172-180.
- Anupam Jena & Tomas Philipson, 2009. "Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption," NBER Working Papers 15032, National Bureau of Economic Research, Inc.
- Aris Angelis & Panos Kanavos, 2016. "Value-Based Assessment of New Medical Technologies: Towards a Robust Methodological Framework for the Application of Multiple Criteria Decision Analysis in the Context of Health Technology Assessment," PharmacoEconomics, Springer, vol. 34(5), pages 435-446, May.
- Mitton, Craig R. & McMahon, Meghan & Morgan, Steve & Gibson, Jennifer, 2006. "Centralized drug review processes: Are they fair?," Social Science & Medicine, Elsevier, vol. 63(1), pages 200-211, July.
- Nicod, Elena & Kanavos, Panos, 2016. "Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study," Health Policy, Elsevier, vol. 120(1), pages 35-45.
- Anders Anell, 2004. "Priority setting for pharmaceuticals," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(1), pages 28-35, February.
- Wouters, Olivier J. & Naci, Huseyin & Samani, Nilesh J, 2015. "QALYs in cost-effectiveness analysis: an overview for cardiologists," LSE Research Online Documents on Economics 63798, London School of Economics and Political Science, LSE Library.
- Angelis, Aris & Kanavos, Panos, 2016. "Value-based assessment of new medical technologies: towards a robust methodological framework for the application of multiple criteria decision analysis in the context of health technology assessment," LSE Research Online Documents on Economics 65148, London School of Economics and Political Science, LSE Library.
- Carroll, Christopher & Kaltenthaler, Eva & FitzGerald, Patrick & Boland, Angela & Dickson, Rumona, 2011. "A thematic analysis of the strengths and weaknesses of manufacturers’ submissions to the NICE Single Technology Assessment (STA) process," Health Policy, Elsevier, vol. 102(2), pages 136-144.
- Nancy Devlin & David Parkin, 2004. "Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 437-452, May.
- Ozieranski, Piotr & McKee, Martin & King, Lawrence, 2012. "The politics of health technology assessment in Poland," Health Policy, Elsevier, vol. 108(2), pages 178-193.
- Michael Drummond & Bengt Jönsson & Frans Rutten & Tom Stargardt, 2011. "Reimbursement of pharmaceuticals: reference pricing versus health technology assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 263-271, June.
- Nicod, Elena & Kanavos, Panos, 2012. "Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisions," Health Policy, Elsevier, vol. 108(2), pages 167-177.
- Ulf Persson & Michael Willis & Knut Ödegaard, 2010. "A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(2), pages 195-203, April.
- McMahon, Meghan & Morgan, Steve & Mitton, Craig, 2006. "The Common Drug Review: A NICE start for Canada?," Health Policy, Elsevier, vol. 77(3), pages 339-351, August.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
- Anderson, Michael & Drummond, Michael & Taylor, David & McGuire, Alistair & Carter, Paul & Mossialos, Elias, 2022. "Promoting innovation while controlling cost: The UK's approach to health technology assessment," Health Policy, Elsevier, vol. 126(3), pages 224-233.
- Fumio Teramae & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies," Sustainability, MDPI, vol. 12(13), pages 1-15, July.
- Jonathan Dando & Maximilian Lebmeier, 2020. "A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-speci," Journal of Innovation and Entrepreneurship, Springer, vol. 9(1), pages 1-28, December.
- Fontrier, Anna-Maria & Kamphuis, Bregtje W. & Kanavos, Panos, 2023. "How can health technology assessment be improved to optimise access to medicines? Results from a Delphi study in Europe," LSE Research Online Documents on Economics 120537, London School of Economics and Political Science, LSE Library.
- Fontrier, Anna-Maria, 2022. "Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations," Social Science & Medicine, Elsevier, vol. 306(C).
- Mónica D. Oliveira & Inês Mataloto & Panos Kanavos, 2019.
"Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art,"
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 891-918, August.
- Oliveira, Mónica D. & Mataloto, Inês & Kanavos, Panos, 2019. "Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art," LSE Research Online Documents on Economics 100763, London School of Economics and Political Science, LSE Library.
- Kanavos, Panos & Visintin, Erica & Gentilini, Arianna, 2023. "Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries," Social Science & Medicine, Elsevier, vol. 331(C).
- Löblová, Olga & Csanádi, Marcell & Ozierański, Piotr & Kaló, Zoltán & King, Lawrence & McKee, Martin, 2019. "Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology," Health Policy, Elsevier, vol. 123(7), pages 630-634.
- Fumio Teramae & Tomohiro Makino & Yeongjoo Lim & Shintaro Sengoku & Kota Kodama, 2020. "International Strategy for Sustainable Growth in Multinational Pharmaceutical Companies," Sustainability, MDPI, vol. 12(3), pages 1-14, January.
- Melanie Büssgen & Tom Stargardt, 2023. "Does health technology assessment compromise access to pharmaceuticals?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(3), pages 437-451, April.
- Riswandy Wasir & Sylvi Irawati & Amr Makady & Maarten Postma & Wim Goettsch & Talitha Feenstra & Erik Buskens, 2019. "The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders," PLOS ONE, Public Library of Science, vol. 14(11), pages 1-14, November.
- Barbara Więckowska & Monika Raulinajtys-Grzybek & Katarzyna Byszek, 2022. "Using the Dynamic SWOT Analysis to Assess Options for Implementing the HB-HTA Model," IJERPH, MDPI, vol. 19(12), pages 1-17, June.
- Csanádi, Marcell & Ozierański, Piotr & Löblová, Olga & King, Lawrence & Kaló, Zoltán & Botz, Lajos, 2019. "Shedding light on the HTA consultancy market: Insights from Poland," Health Policy, Elsevier, vol. 123(12), pages 1237-1243.
- Bengt Jönsson & Grace Hampson & Jonathan Michaels & Adrian Towse & J.-Matthias Graf Schulenburg & Olivier Wong, 2019. "Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 427-438, April.
- Maria Katharina Schweitzer & Manuel Nico Dold & Astrid Genet & Klaus Gossens & Thomas Klein-Hessling & Nils Löffler & Matthias Rabel & Andrej Rasch & Eva-Maria Reuter & Jessica Schmelcher & Natalia Wo, 2024. "Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(5), pages 877-888, July.
- Angelis, A. & Linch, M. & Montibeller, G. & Molina-Lopez, T. & Zawada, A. & Orzel, K. & Arickx, F. & Espin, J. & Kanavos, P., 2020. "Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework," Social Science & Medicine, Elsevier, vol. 246(C).
- Mills, Mackenzie & Kanavos, Panos, 2022. "How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada," Health Policy, Elsevier, vol. 126(11), pages 1130-1143.
- Riswandy Wasir & Sylvi Irawati & Amr Makady & Maarten Postma & Wim Goettsch & Erik Buskens & Talitha Feenstra, 2019. "Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia," PLOS ONE, Public Library of Science, vol. 14(2), pages 1-19, February.
- Livio Garattini & Anna Padula, 2020. "HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(1), pages 1-5, February.
- Sarri, Grammati & Freitag, Andreas & Szegvari, Boglarka & Mountian, Irina & Brixner, Diana & Bertelsen, Neil & Kaló, Zoltán & Upadhyaya, Sheela, 2021. "The Role of Patient Experience in the Value Assessment of Complex Technologies – Do HTA Bodies Need to Reconsider How Value is Assessed?," Health Policy, Elsevier, vol. 125(5), pages 593-601.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Elena Nicod, 2017. "Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four Europ," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 715-730, July.
- Angelis, A. & Linch, M. & Montibeller, G. & Molina-Lopez, T. & Zawada, A. & Orzel, K. & Arickx, F. & Espin, J. & Kanavos, P., 2020. "Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework," Social Science & Medicine, Elsevier, vol. 246(C).
- Maynou, Laia & Cairns, John, 2019. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," Health Policy, Elsevier, vol. 123(2), pages 130-139.
- Angelis, Aris & Kanavos, Panos, 2017. "Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework," Social Science & Medicine, Elsevier, vol. 188(C), pages 137-156.
- Maynou, Laia & Cairns, John, 2018. "What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries," LSE Research Online Documents on Economics 90877, London School of Economics and Political Science, LSE Library.
- Mónica D. Oliveira & Inês Mataloto & Panos Kanavos, 2019.
"Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art,"
The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 891-918, August.
- Oliveira, Mónica D. & Mataloto, Inês & Kanavos, Panos, 2019. "Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art," LSE Research Online Documents on Economics 100763, London School of Economics and Political Science, LSE Library.
- Fischer, Katharina E. & Rogowski, Wolf H. & Leidl, Reiner & Stollenwerk, Björn, 2013. "Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis," Health Policy, Elsevier, vol. 112(3), pages 187-196.
- Katharina E. Fischer & Björn Stollenwerk & Wolf H. Rogowski, 2013. "Link between Process and Appraisal in Coverage Decisions," Medical Decision Making, , vol. 33(8), pages 1009-1025, November.
- Nicod, Elena & Annemans, Lieven & Bucsics, Anna & Lee, Anne & Upadhyaya, Sheela & Facey, Karen, 2019. "HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries," Health Policy, Elsevier, vol. 123(2), pages 140-151.
- Pejcic, Ana V. & Iskrov, Georgi & Jakovljevic, Mihajlo Michael & Stefanov, Rumen, 2018. "Access to orphan drugs – comparison across Balkan countries," Health Policy, Elsevier, vol. 122(6), pages 583-589.
- Nicod, Elena & Kanavos, Panos, 2016. "Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study," Health Policy, Elsevier, vol. 120(1), pages 35-45.
- Fischer, Katharina Elisabeth, 2012. "A systematic review of coverage decision-making on health technologies—Evidence from the real world," Health Policy, Elsevier, vol. 107(2), pages 218-230.
- Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
- Panos Kanavos & Olivier Wouters & Aris Angelis & Panos Kanavos & Gilberto Montibeller, 2017. "Resource Allocation and Priority Setting in Health Care: A Multi-criteria Decision Analysis Problem of Value?," Global Policy, London School of Economics and Political Science, vol. 8, pages 76-83, March.
- Eun-Young Bae & Hui Jeong Kim & Hye-Jae Lee & Junho Jang & Seung Min Lee & Yunkyung Jung & Nari Yoon & Tae Kyung Kim & Kookhee Kim & Bong-Min Yang, 2018. "Role of economic evidence in coverage decision-making in South Korea," PLOS ONE, Public Library of Science, vol. 13(10), pages 1-12, October.
- Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom, 2016. "Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia," Health Policy, Elsevier, vol. 120(10), pages 1115-1122.
- repec:bla:glopol:v:8:y:2017:i:s2:p:76-83 is not listed on IDEAS
- Katharina Fischer & Reiner Leidl, 2014. "Analysing coverage decision-making: opening Pandora’s box?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 899-906, December.
- Andrew Briggs, 2016. "A View from the Bridge: Health Economic Evaluation — A Value‐Based Framework?," Health Economics, John Wiley & Sons, Ltd., vol. 25(12), pages 1499-1502, December.
- Tim H¨ofer & Rüdiger von Nitzsch & Reinhard Madlener, 2020. "Using Value-Focused Thinking and Multicriteria Decision Making to Evaluate Energy Transition Alternatives," Decision Analysis, INFORMS, vol. 17(4), pages 330-355, December.
- Jennifer Whitty & Paul Scuffham & Sharyn Rundle-Thielee, 2011. "Public and decision maker stated preferences for pharmaceutical subsidy decisions," Applied Health Economics and Health Policy, Springer, vol. 9(2), pages 73-79, March.
More about this item
Keywords
Health technology assessment (HTA); Value assessment; Innovative medicines; High cost medicines; Pharmaceutical policy; European Union; Systematic review; Expert consultation;All these keywords.
JEL classification:
- I - Health, Education, and Welfare
- I1 - Health, Education, and Welfare - - Health
- I10 - Health, Education, and Welfare - - Health - - - General
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:19:y:2018:i:1:d:10.1007_s10198-017-0871-0. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.